March 14- The benefits of Endo International Plc's long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration concluded on Tuesday. However, data shows that while nasal abuse has reduced with the reformulation, rates of intravenous abuse increased, FDA staff noted in their review on Thursday,...
March 14- The benefits of Endo International Plc's long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration concluded on Tuesday. The Centers for Disease Control and Prevention estimates at least 91 Americans succumb every day to opioid overdose. Data shows that while nasal abuse has reduced...
March 14- The benefits of Endo International Plc's long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration concluded on Tuesday. The drug, Opana ER, is a long-acting variation of oxymorphine that is intended to treat pain severe enough to require daily, around-the-clock, long-term opioid...
Attorney General Jeff Sessions is signaling that he will crack down on federal drug laws.
Trump wants to deregulate the Food and Drug Administration. He chose the right guy for the job, Vox reports.
Promising new research suggests that marijuana could be used to treat Alzheimer's, but there's a major roadblock: the federal government.
Bolivian President Evo Morales has signed a new bill which almost doubles the area of land that can be used for legal coca production.
Biotech stocks might be in a slump, but there's an upside, one analyst says.
This 100% drug-free wearable claims to relieve you from chronic pain by using pain relief technology.
Mylan CEO Heather Bresch shares her views on the pharmaceutical industry in an interview Friday on CNBC's "Power Lunch."
The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.
President Donald Trump told Congress that more needs to be done to bring down "artificially high" prices for drugs, while at the same time praising a drug that turns out to cost $300,000 per year.
CNBC's Carolin Roth discusses how the positive findings of Roche's Aphinity study is impacting investment in the business.
Amicus Therapeutics CEO Crowley is optimistic about Trump's plans to work with the pharma industry, proposing change for good.
The stock slid sharply in morning trading before rebounding to climb about 1 percent higher Wednesday.
Shares of EpiPen maker Mylan climbed on the heels of the company reporting fourth-quarter earnings that topped expectations.
A Philippine Senator and staunch critic of President Rodrigo Duterte's war on drugs was arrested on Friday.
Jim Cramer goes through his list of lightning round callers, and says it is time for Gilead to make a move.
David Ricks, Eli Lilly CEO, weighs in on tax reform priorities, border adjustment tax and drug pricing.
Feb 21- Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone. The Centers for Disease Control and Prevention estimates that 91 Americans die every day from opioid overdoses. Amphastar already sells...